WASF2 (WASP family member 2) is a cytoskeletal regulatory protein that functions as a downstream effector of tyrosine kinase receptors and small GTPases, promoting actin filament formation through the WAVE complex and Arp2/3 complex interactions 1. Beyond its classical role in actin cytoskeleton organization and lamellipodia formation, WASF2 has emerged as a multifunctional regulator with disease relevance across diverse pathologies. In immune homeostasis, WASF2 directly binds and inhibits mTOR activation by preventing mTOR-RAPTOR/RICTOR interactions, maintaining T cell homeostasis and preventing autoimmunity 1. Conversely, WASF2 exhibits oncogenic properties in multiple cancers: it promotes gastric cancer migration, invasion, and metastasis through actin polymerization-driven membrane protrusion formation 2, and similarly enhances ovarian cancer cell proliferation, migration, and invasion 3. In hepatocellular carcinoma, WASF2 overexpression driven by promoter hypomethylation correlates with poor prognosis and facilitates tumor growth and metastasis 4. Notably, WASF2 shows context-dependent functions: it acts as a tumor suppressor in head and neck squamous cell carcinoma when unmethylated 5. Clinically, circulating WASF2 mRNA in exosomes shows promise as a pancreatic cancer biomarker with superior diagnostic accuracy compared to CA19-9 6. Additionally, WASF2 regulation by microRNAs (miR-146a and miR-1253) suggests therapeutic potential for cancer and hypertension-related vascular dysfunction 2, 7.